LAI plus multi-drug regimen

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mycobacterium Infections, Nontuberculous

Conditions

Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical

Trial Timeline

Oct 1, 2016 → Dec 31, 2019

NCT ID

NCT03038178

About LAI plus multi-drug regimen

LAI plus multi-drug regimen is a phase 2 stage product being developed by Insmed for Mycobacterium Infections, Nontuberculous. The current trial status is completed. This product is registered under clinical trial identifier NCT03038178. Target conditions include Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03038178	Phase 2	Completed	Oct 1, 2016	Dec 31, 2019	Mycobacterium Infections, Nontuberculous

Competing Products

20 competing products in Mycobacterium Infections, Nontuberculous

See all competitors

Product	Company	Stage	Hype Score
Trifluridine	Amgen	Pre-clinical	22
clarithromycin, rifabutin	Pfizer	Approved	84
Azithromycin	Pfizer	Pre-clinical	22
Ethambutol hydrochloride + Clarithromycin + Azithromycin	Pfizer	Phase 3	76
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Approved	84
Tigecycline	Pfizer	Phase 2	51
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	84
ALIS + Azithromycin + Ethambutol + ELC	Insmed	Phase 3	74
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)	Insmed	Phase 3	74
Liposomal amikacin for inhalation (LAI) + placebo	Insmed	Phase 2	49
LAI (Liposomal Amikacin for Inhalation) 590 mg	Insmed	Phase 3	74
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin	Innoviva	Phase 2	47
Molgramostim nebulizer solution	Savara	Phase 2	47
Inhaled molgramostim + Antimycobacterial regimen	Savara	Phase 2	47
Epetraborole + Epetraborole + Placebo + Placebo	AN2 Therapeutics	Phase 2	44
SPR720 + Placebo + Open-label Standard of Care	Spero Therapeutics	Phase 2	44
RHB-204 + Placebo	RedHill Biopharma	Phase 3	69

Other Products from Insmed

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.Phase 3

Treprostinil Palmitil Inhalation Powder + PlaceboPhase 3

ALIS + Azithromycin + Ethambutol + ELCPhase 3

LAI 590 mg + Multi-drug regimenPhase 3